Amneal: Phase 3 Comparison of IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Published

 IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses

 

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD). The study met its primary and secondary endpoints finding that IPX203 provided more hours of “Good On” time per day, less “Off” time per day, and more “Good On” time per dose than optimized IR CD/LD, even when dosed less frequently. “Good On” time is defined as the sum of “On” time without dyskinesia and “On” time with non-troublesome dyskinesia. The manuscript titled, “IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease,” was published online on August 14, 2023.

https://www.biospace.com/article/releases/jama-neurology-publishes-phase-3-study-results-comparing-ipx203-to-immediate-release-carbidopa-levodopa-for-parkinson-s-disease/